Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.49 |
| ▸ | AHR | P35869 | 2/20 | 0.47 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.43 |
| ▸ | PCSK9 | Q8NBP7 | 4/20 | 0.43 |
| ▸ | F2 | P00734 | 1/20 | 0.43 |
| ▸ | KDM5A | P29375 | 1/20 | 0.42 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.42 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.42 |
| ▸ | KIF11 | P52732 | 2/20 | 0.41 |
| ▸ | GUSB | P08236 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7492791 | 0.84 | LOXL2 (0.49) | LOXL2AHRPCSK9F2KIF11 | |
| SCHEMBL17027129 | 0.83 | F2 (0.55) | F2KDM5AKDM4CKDM5BKIF11 | |
| SCHEMBL6994522 | 0.82 | LOXL2 (0.53) | LOXL2AHRPCSK9F2GUSB | |
| SCHEMBL30105384 | 0.81 | LOXL2 (0.60) | LOXL2AHRPCSK9F2 | |
| SCHEMBL3193871 | 0.81 | LOXL2 (0.60) | LOXL2AHRPCSK9F2 | |
| SCHEMBL18477010 | 0.81 | LOXL2 (0.53) | LOXL2PCSK9F2KDM5AKDM4C | |
| Hydrochloric Acid SCHEMBL27754931 | 0.80 | LOXL2 (0.58) | LOXL2AHRF2 | |
| Bromide SCHEMBL30437340 | 0.80 | LOXL2 (0.58) | LOXL2AHRPCSK9F2 | |
| SCHEMBL7489457 | 0.80 | AHR (0.49) | LOXL2AHRPCSK9KIF11GUSB | |
| SCHEMBL6619148 | 0.79 | PCSK9 (0.57) | LOXL2AHRPCSK9F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210300869-A1 | MODULATORS OF ROR-GAMMA | VITAE PHARMACEUTICAL, LLC | 2021-09-30 | — | — | US | disclosed |
| US-10829448-B2 | Substituted benzoimidazoles as modulators of ROR-γ | VITAE PHARMACEUTICALS, LLC (US) | 2020-11-10 | — | — | US | disclosed |
| US-20200062707-A1 | MODULATORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, INC. | 2020-02-27 | — | — | US | disclosed |
| US-10301261-B2 | Substituted indoles as modulators of ROR-gamma | VITAE PHARMACEUTICALS, LLC (US) | 2019-05-28 | — | — | US | disclosed |
| US-20180222860-A1 | MODULATORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, LLC | 2018-08-09 | — | — | US | disclosed |
| EP-1322646-A1 | 2-(1H-INDOL-3-YL)-2-OXO-ACETIC ACID AMIDES WITH ANTITUMOR ACTIVITY | Novuspharma S.p.A. (IT) | 2003-07-02 | — | — | EP | disclosed |
| WO-2002008225-A1 | 2-(1H-INDOL-3-YL)-2-OXO-ACETIC ACID AMIDES WITH ANTITUMOR ACTIVITY | NOVUSPHARMA S.P.A. (IT) | 2002-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10301261-B2 | Substituted indoles as modulators of ROR-gamma | RORB, RORC, RORA | LOXL2 3162/4885AHR 25/4885MCHR1 207/4885 |
| US-20200062707-A1 | MODULATORS OF ROR-GAMMA | RORB, RORC, RORA | LOXL2 3226/4885AHR 300/4885MCHR1 446/4885 |
| US-20180222860-A1 | MODULATORS OF ROR-GAMMA | RORB, RORC, RORA | LOXL2 3226/4885AHR 300/4885MCHR1 446/4885 |
| US-10829448-B2 | Substituted benzoimidazoles as modulators of ROR-γ | RORC, RORB, RORA | LOXL2 3747/4885AHR 34/4885MCHR1 1558/4885 |
| US-20210300869-A1 | MODULATORS OF ROR-GAMMA | RORC, RORB, RORA | LOXL2 3749/4885AHR 49/4885MCHR1 1051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.